v3.26.1
Asset Purchase Agreement (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Dec. 10, 2025
Sep. 12, 2025
Mar. 31, 2026
Sep. 30, 2025
Dec. 31, 2025
Asset Purchase Agreement [Line Items]          
Consideration purchase of assets   $ 50,000      
Annual net sales percentage     2.00%    
Haisco Licensing Agreement [Member]          
Asset Purchase Agreement [Line Items]          
Annual net sales percentage     50.00%    
Asset Purchase Agreement [Member]          
Asset Purchase Agreement [Line Items]          
Consideration asset $ 15,000,000 50,000      
Direct transaction costs       $ 151,216  
Asset Purchase Agreement [Member] | eXIthera Pharmaceuticals, Inc. [Member]          
Asset Purchase Agreement [Line Items]          
Consideration asset   $ 15,000,000      
Veralox APA [Member]          
Asset Purchase Agreement [Line Items]          
Consideration purchase of assets 200,000   $ 300,000    
Consideration asset $ 331,797        
Annual net sales percentage     5.00%    
Direct transaction costs         $ 131,797
Royalty revenue received     $ 200,000,000    
Minimum [Member] | Veralox APA [Member]          
Asset Purchase Agreement [Line Items]          
Royalty expense     10,000    
Maximum [Member] | Veralox APA [Member]          
Asset Purchase Agreement [Line Items]          
Royalty expense     50,000    
Veralox Therapeutics Inc. [Member] | Veralox APA [Member]          
Asset Purchase Agreement [Line Items]          
Consideration asset     $ 200,000    
Royalty [Member] | Veralox APA [Member]          
Asset Purchase Agreement [Line Items]          
Annual net sales percentage     3.00%    
License agreement amount     $ 200,000,000